{
  "patent_number": "US 20160168227",
  "country": "US",
  "title": "How an mRNA Vaccine for Lung Cancer Teaches the Immune System to Fight",
  "original_title": "Composition and vaccine for treating lung cancer",
  "summary": "This patent describes a specific mRNA vaccine designed to treat lung cancer by instructing the body's cells to produce six distinct tumor proteins, thereby training the immune system to recognize and attack cancer cells.",
  "what_it_does": "This patent describes a special recipe, called a composition, for an mRNA vaccine to fight lung cancer. The core idea is to use messenger RNA (mRNA) that carries instructions for making six specific proteins, or 'antigens,' found on lung cancer cells. These antigens are 5T4, Survivin, NY-ESO-1, MAGE-C1, MAGE-C2, and MUC1 (Claim 1). When this mRNA is introduced into a mammal, like a human, the body's cells read these instructions and produce these cancer-related proteins. This process then teaches the immune system to recognize these proteins as foreign, prompting it to launch an attack against any cells displaying them, which includes lung cancer cells. The patent also details ways to make the mRNA more effective, such as making it more stable (Claim 7), increasing its G/C content (Claim 8), and adding special caps and tails (like a 5' cap and poly(A) and poly(C) tails) to the mRNA molecule (Claim 10) to improve its lifespan and protein production within the body.",
  "what_it_does_not_cover": [
    "Does not cover mRNA compositions that encode only some, but not all six, of the specified antigens (5T4, Survivin, NY-ESO-1, MAGE-C1, MAGE-C2, and MUC1).",
    "Does not cover vaccines for lung cancer that use different types of molecules, such as DNA, viral vectors, or protein-based vaccines, instead of mRNA.",
    "Does not cover compositions designed to treat other types of cancer, as the claims specifically mention 'treatment of lung cancer'.",
    "Does not cover compositions that use a different set of antigens for lung cancer, even if delivered by mRNA.",
    "Does not cover mRNA that lacks specific stabilizing features like a 5' cap, poly(A) tail, or increased G/C content, as these are claimed modifications."
  ],
  "filed": "2016-02-19",
  "granted": null,
  "expires": "2036-02-19",
  "status": "active",
  "holder": "Curevac AG",
  "holder_url": "https://patentbrief.org/company/curevac-ag",
  "inventors": [
    {
      "name": "Karl-Josef Kallen",
      "url": "https://patentbrief.org/inventor/karl-josef-kallen"
    },
    {
      "name": "Ulrike Gnad-Vogt",
      "url": "https://patentbrief.org/inventor/ulrike-gnad-vogt"
    },
    {
      "name": "Mariola Fotin-Mleczek",
      "url": "https://patentbrief.org/inventor/mariola-fotin-mleczek"
    }
  ],
  "times_cited": 80,
  "tags": [
    "biotech",
    "pharmaceutical",
    "oncology",
    "gene_editing"
  ],
  "abstract": "The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.",
  "url": "https://patentbrief.org/patent/us/20160168227/composition-and-vaccine-for-treating-lung-cancer",
  "markdown_url": "https://patentbrief.org/patent/us/20160168227/composition-and-vaccine-for-treating-lung-cancer/md",
  "google_patents_url": "https://patents.google.com/patent/US20160168227",
  "relatedPatents": [
    {
      "patentNumber": "20160166668",
      "countryCode": "US",
      "title": "How an mRNA Vaccine Targets Prostate Cancer with Six Antigens",
      "url": "https://patentbrief.org/patent/us/20160166668/composition-and-vaccine-for-treating-prostate-cancer"
    },
    {
      "patentNumber": "10314897",
      "countryCode": "US",
      "title": "How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer",
      "url": "https://patentbrief.org/patent/us/10314897/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-ca"
    },
    {
      "patentNumber": "12168044",
      "countryCode": "US",
      "title": "Treating Liver Cancer with Specially Trained Immune Cells",
      "url": "https://patentbrief.org/patent/us/12168044/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-non-small-"
    },
    {
      "patentNumber": "11542303",
      "countryCode": "US",
      "title": "How a Specific Peptide Boosts the Immune System Against Cancer",
      "url": "https://patentbrief.org/patent/us/11542303/peptides-and-combination-thereof-for-use-in-the-immunotherapy-against-cancers"
    },
    {
      "patentNumber": "8278036",
      "countryCode": "US",
      "title": "How Modified RNA Tricks Cells Into Making Proteins Without Triggering Attacks",
      "url": "https://patentbrief.org/patent/us/8278036/rna-containing-modified-nucleosides-and-methods-of-use-thereof"
    }
  ]
}